[{"id":"089a9873-0dbf-4d04-a926-ae092495901f","acronym":"ComboMATCH","url":"https://clinicaltrials.gov/study/NCT05554380","created_at":"2022-09-26T14:56:10.419Z","updated_at":"2025-02-25T12:38:22.753Z","phase":"Phase 2","brief_title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554380 - ComboMATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT2","pipe":" | ","alterations":" AKT1 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-24"},{"id":"b32f23eb-9a26-4345-b81c-19e88cc236d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01226316","created_at":"2021-01-18T04:55:40.912Z","updated_at":"2024-07-02T16:35:04.747Z","phase":"Phase 1","brief_title":"Safety, Tolerability \u0026 Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","source_id_and_acronym":"NCT01226316","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation","tags":["HER-2 • ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-09"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"6ed06cab-c7c7-450b-93d9-67848afd9e45","acronym":"CICLADES","url":"https://clinicaltrials.gov/study/NCT03318263","created_at":"2021-01-18T16:23:13.868Z","updated_at":"2024-07-02T16:35:40.862Z","phase":"","brief_title":"CIrCuLAting Dna ESr1 Gene Mutations Analysis","source_id_and_acronym":"NCT03318263 - CICLADES","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2 • ER • PIK3CA • AKT1","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PIK3CA • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-08-04"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"cba504e9-1b20-4258-b52e-a18251022778","acronym":"IceCAP","url":"https://clinicaltrials.gov/study/NCT03673787","created_at":"2021-01-18T18:01:13.221Z","updated_at":"2024-07-02T16:36:13.368Z","phase":"Phase 1/2","brief_title":"A Trial of Ipatasertib in Combination With Atezolizumab","source_id_and_acronym":"NCT03673787 - IceCAP","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" PIK3CA • PTEN • AKT2","pipe":" | ","alterations":" PIK3CA mutation • AKT1 mutation","tags":["PIK3CA • PTEN • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-04-08"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"},{"id":"ebc320e8-5c03-4ecc-88dc-a788f595b07f","acronym":"ALCAPONE","url":"https://clinicaltrials.gov/study/NCT02281214","created_at":"2021-01-18T10:44:37.756Z","updated_at":"2024-07-02T16:37:04.244Z","phase":"","brief_title":"NGS Genome Analysis in Personalisation of Lung Cancer Treatment","source_id_and_acronym":"NCT02281214 - ALCAPONE","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 10/24/2014","start_date":" 10/24/2014","primary_txt":" Primary completion: 11/17/2014","primary_completion_date":" 11/17/2014","study_txt":" Completion: 11/17/2018","study_completion_date":" 11/17/2018","last_update_posted":"2019-01-04"},{"id":"69112ba3-2ae8-4897-864e-b49a99d79bf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771404","created_at":"2021-01-18T18:39:31.761Z","updated_at":"2024-07-02T16:37:04.768Z","phase":"","brief_title":"NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"","source_id_and_acronym":"NCT03771404","lead_sponsor":"Hellenic Oncology Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-11"},{"id":"315599d2-2faa-4fa8-9734-19252ebf4382","acronym":"","url":"https://clinicaltrials.gov/study/NCT01915576","created_at":"2021-01-18T08:38:20.529Z","updated_at":"2025-02-25T17:06:56.587Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients","source_id_and_acronym":"NCT01915576","lead_sponsor":"Bayer","biomarkers":" AKT1","pipe":" | ","alterations":" AKT1 E17K • AKT1 mutation","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 E17K • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY 1125976"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-12-28"}]